Giredestrant vs Other Oral SERDs: How Roche’s Wilserdly Compares

Nov 20, 2026 | Pharma

Image Source: Generated by Google Gemini
Written by: LSDN Editorial Team
On behalf of: Life Science Daily News

Giredestrant has become the latest oral SERD approved in the US for ESR1-mutated breast cancer. It joins elacestrant, imlunestrant and camizestrant. Its distinguishing feature is the partner drug. It is the only one of the four approved alongside everolimus. The comparison below also includes vepdegestrant, an oral degrader that is not a SERD but is used in the same patients. No trial has yet compared any of them directly. The FDA approved giredestrant with everolimus on 16 November 2026, under the brand name Wilserdly.

How Does Giredestrant Compare With Other Oral SERDs?

The short answer is that the comparison cannot yet be made on outcomes. Each approval rests on a different trial, a different control arm and a different line of therapy. What can be compared is the label. That means the patients each drug treats, its partner drug and the mutation test.

On those terms, giredestrant stands apart in two ways. First, it is paired with everolimus, an mTOR inhibitor, rather than given alone or with a CDK4/6 inhibitor. Second, its companion diagnostic is FoundationOne Liquid CDx. By contrast, the FDA lists Guardant360 CDx for elacestrant, imlunestrant, vepdegestrant and camizestrant.

What the FDA Approved on 16 November

The FDA approved the combination four weeks ahead of its goal date, according to the agency. The label covers adults with ER-positive, HER2-negative, ESR1-mutated locally advanced or metastatic breast cancer. The mutation must be detected by an FDA-authorised test.

Eligible disease must have recurred during or after completing endocrine-based adjuvant therapy. Alternatively, it must have progressed on at least one endocrine-based regimen in the metastatic setting. The review ran under Project Orbis with Health Canada and Israel’s Ministry of Health.

The indication itself does not mention prior CDK4/6 inhibitor treatment. However, Roche said evERA enrolled patients who had received a CDK4/6 inhibitor and endocrine therapy. The recommended dose is 30 mg of giredestrant once daily, with everolimus dosed according to its own label. In Roche’s announcement, the company described Wilserdly as “a next-generation oral SERD”.

The evERA Trial Results

Approval rests on evERA Breast Cancer (NCT05306340), a Phase 3, randomised, open-label trial. It enrolled 373 patients, 207 of whom had ESR1-mutated tumours. Patients received giredestrant or a physician’s choice of exemestane, fulvestrant or tamoxifen. Both arms also received everolimus 10 mg daily.

The full results were published in The New England Journal of Medicine in October 2026. Erica L. Mayer, Director of Breast Cancer Clinical Research, Dana-Farber Cancer Institute, is the first author. In the Roche release, she called the regimen one “offering patients prolonged disease control through a fully oral therapeutic option”.

Progression-Free Survival

The primary endpoint was investigator-assessed progression-free survival, tested first in ESR1-mutated patients, then in all patients. In the ESR1-mutated group, median progression-free survival was 10.0 months with giredestrant against 5.5 months with control. The hazard ratio was 0.38 (95% CI 0.27 to 0.54). The objective response rate in that group was 27 per cent against 14 per cent, the FDA reported.

In the full population, medians were 8.8 and 5.5 months. The hazard ratio was 0.56 (95% CI 0.44 to 0.71). Even so, the FDA indication covers only ESR1-mutated disease. Overall survival was immature at the interim analysis. In ESR1-mutated patients, the hazard ratio for death was 0.62 (95% CI 0.38 to 1.02). That result did not cross the prespecified significance boundary.

Safety Findings From the Same Dataset

According to the NEJM paper, 98.9 per cent of the giredestrant group had an adverse event. The control figure was 96.8 per cent. Serious adverse events were more frequent with giredestrant, at 29.1 per cent against 23.1 per cent. Everolimus discontinuation for adverse events reached 17.0 per cent with giredestrant and 11.8 per cent with control. Giredestrant or the comparator endocrine drug was stopped in 8.2 per cent and 6.5 per cent respectively.

Stomatitis was the most common event, at 47.3 per cent with giredestrant and 48.9 per cent with control. Any-grade pneumonitis affected 17.0 per cent against 12.4 per cent. Grade 3 or 4 pneumonitis was equal, at 2.7 per cent in each arm. Bradycardia occurred in 3.8 per cent against 0.5 per cent, and all cases were grade 1. Fatal adverse events occurred in 2.7 per cent of each arm. The US label carries warnings for bradycardia and embryo-fetal toxicity.

How the Other Oral SERD Approvals Differ

Elacestrant and Imlunestrant

Elacestrant (Orserdu) received FDA approval on 27 January 2023 as a single agent. In the EMERALD trial’s ESR1-mutated group, median progression-free survival was 3.8 months against 1.9 months. The hazard ratio was 0.55 (95% CI 0.39 to 0.77). Controls received fulvestrant or an aromatase inhibitor.

Imlunestrant (Inluriyo) was approved on 25 September 2025 on the basis of EMBER-3. In ESR1-mutated patients, medians were 5.5 months against 3.8 months with fulvestrant or exemestane. The hazard ratio was 0.62 (95% CI 0.46 to 0.82). On 18 September 2026, the FDA added a combination with abemaciclib for ESR1-mutated disease. That approval drew on an exploratory subgroup of 159 patients. Their median was 11.1 months, against 5.5 months for imlunestrant alone.

Camizestrant and Vepdegestrant

Camizestrant (Etcamah) received accelerated approval on 4 September 2026, in combination with a CDK4/6 inhibitor. Its setting is earlier than the others. Patients switch when an ESR1 mutation appears during first-line aromatase inhibitor and CDK4/6 therapy. In SERENA-6, median progression-free survival was 16 months against 9.2 months. The hazard ratio was 0.44 (95% CI 0.31 to 0.60). The camizestrant approval in September made ctDNA-detected mutation a trigger for a change of therapy.

Vepdegestrant (Veppanu), approved on 1 May 2026, also degrades the oestrogen receptor. It is a PROTAC protein degrader, however, rather than a SERD. In VERITAC-2, ESR1-mutated patients had a median of 5 months against 2.1 months with fulvestrant. The hazard ratio was 0.57 (95% CI 0.42 to 0.77).

The table below sets out each approval on the same terms.

Oral SERD approvals for ESR1-mutated breast cancer at a glance
Drug (brand) FDA approval Pivotal trial Given with Companion test Median PFS, ESR1-mutated (months)
Giredestrant (Wilserdly) 16 Nov 2026 evERA Everolimus FoundationOne Liquid CDx 10.0 vs 5.5 (HR 0.38)
Elacestrant (Orserdu) 27 Jan 2023 EMERALD Alone Guardant360 CDx 3.8 vs 1.9 (HR 0.55)
Imlunestrant (Inluriyo) 25 Sep 2025 EMBER-3 Alone, or with abemaciclib* Guardant360 CDx 5.5 vs 3.8 (HR 0.62)
Camizestrant (Etcamah) 4 Sep 2026 (accelerated) SERENA-6 CDK4/6 inhibitor Guardant360 CDx 16.0 vs 9.2 (HR 0.44)†
Vepdegestrant (Veppanu)‡ 1 May 2026 VERITAC-2 Alone Guardant360 CDx 5.0 vs 2.1 (HR 0.57)

* The abemaciclib combination was added on 18 September 2026, based on an exploratory subgroup of 159 patients (11.1 vs 5.5 months).
† Patients switched treatment when an ESR1 mutation was detected, before their disease progressed on scans. Progression-free survival is measured from that switch.
‡ Vepdegestrant is a PROTAC protein degrader rather than a SERD. It is included because it targets the same patients.
Figures come from separate trials with different control arms and patient groups, and should not be compared directly. Source: FDA approval notifications.

Why Cross-Trial Comparisons Mislead

Setting each oral SERD’s medians side by side invites a ranking that the data do not support. The evERA control arm included everolimus. By contrast, EMERALD, EMBER-3 and VERITAC-2 compared against endocrine therapy alone. A combination trial and a monotherapy trial answer different questions.

Populations also differ. SERENA-6 switched patients before radiological progression, while the other trials enrolled patients after it. Assessment methods vary as well. evERA used investigator review, whereas VERITAC-2 used blinded independent central review. Each label also names its own companion diagnostic.

For clinicians, the practical question is therefore fit rather than rank. Prior therapy, tolerance of everolimus and the test already used will shape which oral SERD suits a patient.

Where Giredestrant Stands in the UK and Europe

A search of the electronic medicines compendium (emc) on 20 November 2026 returned no giredestrant entry. Roche said only that “additional regulatory filings and development activities are underway in markets outside the US”. Its release did not name the European Medicines Agency or the MHRA.

Two comparators are further along in the UK. Under TA1036, NICE recommends elacestrant after progression on endocrine treatment plus a CDK4/6 inhibitor. The recommendation applies only after at least 12 months of that prior treatment. It also depends on a commercial arrangement with the company. Meanwhile, imlunestrant was first authorised in the UK on 24 February 2026 as monotherapy, according to its emc SmPC. That emc entry was last updated on 9 April 2026.

What Happens Next

The next regulatory test for giredestrant comes within days. Roche said the FDA is due to decide on an adjuvant application by 30 November 2026. It is based on the lidERA trial, covers early breast cancer and is under priority review. If approved, giredestrant would extend beyond the advanced setting where every other oral SERD label sits.

Roche also lists four further Phase 3 trials of giredestrant as pending: pionERA, heredERA, novERA and kalitERA. Mature overall survival from evERA will matter too. Until then, any comparison between these drugs will rest on labels, not head-to-head evidence.

    References:
    1. US Food and Drug Administration (2026). FDA approves giredestrant in combination with everolimus for ER-positive, HER2-negative, ESR1-mutated locally advanced or metastatic breast cancer. https://www.fda.gov/drugs/cancer-approvals/fda-approves-giredestrant-combination-everolimus-er-positive-her2-negative-esr1-mutated-locally
    2. Mayer EL, et al. (2026). Giredestrant plus Everolimus in Advanced Breast Cancer. The New England Journal of Medicine, 395(13), 1285 to 1298. https://doi.org/10.1056/NEJMoa2602457
    3. Roche (2026). FDA approves Roche’s Wilserdly (giredestrant), a next-generation oral SERD, for ER-positive, ESR1-mutated advanced breast cancer. https://www.roche.com/media/releases/med-cor-2026-11-16b
    4. US Food and Drug Administration (2023). FDA approves elacestrant for ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer. https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-elacestrant-er-positive-her2-negative-esr1-mutated-advanced-or-metastatic-breast-cancer
    5. US Food and Drug Administration (2025). FDA approves imlunestrant for ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer. https://www.fda.gov/drugs/cancer-approvals/fda-approves-imlunestrant-er-positive-her2-negative-esr1-mutated-advanced-or-metastatic-breast
    6. US Food and Drug Administration (2026). FDA approves imlunestrant in combination with abemaciclib for ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer. https://www.fda.gov/drugs/cancer-approvals/fda-approves-imlunestrant-combination-abemaciclib-er-positive-her2-negative-esr1-mutated-advanced-or
    7. US Food and Drug Administration (2026). FDA grants accelerated approval to camizestrant with a CDK4/6 inhibitor for ESR1-mutated, HR-positive, HER2-negative breast cancer. https://www.fda.gov/drugs/cancer-approvals/fda-grants-accelerated-approval-camizestrant-cdk46-inhibitor-esr1-mutated-hr-positive-her2-negative
    8. US Food and Drug Administration (2026). FDA approves vepdegestrant for ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer. https://www.fda.gov/drugs/cancer-approvals/fda-approves-vepdegestrant-er-positive-her2-negative-esr1-mutated-advanced-or-metastatic-breast
    9. NICE (accessed 2026). TA1036: Elacestrant for treating oestrogen receptor-positive HER2-negative advanced breast cancer with an ESR1 mutation after endocrine treatment. Recommendations. https://www.nice.org.uk/guidance/TA1036/chapter/recommendations
    10. Electronic medicines compendium (2026). Inluriyo 200 mg film-coated tablets, Summary of Product Characteristics. https://www.medicines.org.uk/emc/product/102031/smpc
    All content is published for informational purposes only and does not constitute medical, legal, or investment advice. For more information, see our Terms and Conditions.

    Articles that may be of interest

    Articles that may be of interest

    Neladalkib vs Lorlatinib: How GSK’s New ALK Drug Compares

    Neladalkib vs Lorlatinib: How GSK’s New ALK Drug Compares

    Anyone searching neladalkib vs lorlatinib will find no head-to-head trial. No published evidence yet shows which drug is better. What the data do show is narrower. The US Food and Drug Administration (FDA) granted accelerated approval to neladalkib, branded Nelkarmi,...

    read more
    OLN324 vs Vabysmo: How J&J’s $2.2bn Eye Drug Compares

    OLN324 vs Vabysmo: How J&J’s $2.2bn Eye Drug Compares

    How does OLN324 compare with Vabysmo? In the only head-to-head data found, it dried the retina faster in diabetic macular oedema. However, differences in durability and vision were small. That evidence comes from a 164-patient Phase 1b trial, and no Phase 3 comparison...

    read more